IC ICLR Icon Plc Loading... : Bullish and Bearish Analyst Opinions

IQVIA disclosed a new customer segment breakdown, with EVP (emerging biopharma) being a much larger part of revenue (35%) than previously disclosed, positioning them as the largest EVP provider. — Signals potential re-rating of IQVIA's growth vs. peers, as EVP segment is growing 2-3x faster than large pharma, suggesting structural advantage over other CROs.

IQVIA noted that cancellations in Q4 were 'slightly above the normal range' due to idiosyncratic reasons, but overall demand metrics (pipeline, RFP flow, win rates) improved, and backlog reached a record high. — Despite a slightly elevated cancellation rate, the strong bookings and growth in backlog indicate a healthy overall demand environment for clinical research services, a positive signal for the whole CRO sector.